Want to take quizzes and track your credits?
The COVID-19 pandemic has had a substantial effect on cancer care.1 The recent widespread availability of vaccines against SARS-CoV-2 is a promising strategy to prevent COVID-19–associated mortality. However, previous reports have shown a high hesitancy rate to receive a COVID-19 vaccine among oncologic patients.2,3 Because breast cancer is the most commonly diagnosed malignant neoplasm,4 it is imperative to evaluate the specific concerns regarding COVID-19 vaccination among patients with this disease.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Accepted for Publication: April 21, 2021.
Published Online: June 10, 2021. doi:10.1001/jamaoncol.2021.1962
Corresponding Author: Cynthia Villarreal-Garza, MD, DSc, Breast Cancer Center, Hospital Zambrano Hellion TecSalud, Tecnologico de Monterrey, Batallón de San Patricio 112, Real de San Agustín, 66278 San Pedro Garza García, Nuevo León, Mexico (firstname.lastname@example.org).
Author Contributions: Dr Villarreal-Garza had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: All authors.
Acquisition, analysis, or interpretation of data: Villarreal-Garza, Vaca-Cartagena, Becerril-Gaitan, Ferrigno, Mesa-Chavez.
Drafting of the manuscript: Villarreal-Garza, Vaca-Cartagena, Becerril-Gaitan, Ferrigno, Mesa-Chavez.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Vaca-Cartagena, Becerril-Gaitan.
Administrative, technical, or material support: Villarreal-Garza, Alejandra Platas, Ana Platas.
Supervision: Villarreal-Garza, Mesa-Chavez.
Conflict of Interest Disclosures: Dr Villarreal-Garza reported grants from AstraZeneca and Roche; speaking honoraria from Roche, Myriad Genetics, Novartis, Pfizer, and Eli Lilly; travel fees from Roche, MSD Oncology, and Pfizer; and advisory roles at Roche, Novartis, Pfizer, and Eli Lilly. No other disclosures were reported.
Additional Contributions: We thank the organizations that helped to disseminate the survey: Médicos e Investigadores en la Lucha contra el Cáncer de Mama, Salvati AC, Coalición Mexicana por la Salud Mamaria, Cáncer Warriors de México, Red Contra el Cáncer, Programa de Supervivientes del Instituto Nacional de Cancerología, Pro Oncavi, Grupo Vida Plena Después Del Cáncer AC, Fundación Unidas Contigo, and Encauza.
You currently have no searches saved.
You currently have no courses saved.